NO20010293L - Anvendelse av glukoseopptaks-enhancer for redusering av post- ischemisk skade av hjertet - Google Patents

Anvendelse av glukoseopptaks-enhancer for redusering av post- ischemisk skade av hjertet

Info

Publication number
NO20010293L
NO20010293L NO20010293A NO20010293A NO20010293L NO 20010293 L NO20010293 L NO 20010293L NO 20010293 A NO20010293 A NO 20010293A NO 20010293 A NO20010293 A NO 20010293A NO 20010293 L NO20010293 L NO 20010293L
Authority
NO
Norway
Prior art keywords
glucose uptake
ischemic heart
reduce post
heart damage
uptake enhancer
Prior art date
Application number
NO20010293A
Other languages
English (en)
Norwegian (no)
Other versions
NO20010293D0 (no
Inventor
Antoine Michel Alain Bril
Robin Edwin Buckingham
Nassirah Khandoudi
Original Assignee
Smithkline Beecham Plc
Smithkline Beecham Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9815872.8A external-priority patent/GB9815872D0/en
Priority claimed from GBGB9815871.0A external-priority patent/GB9815871D0/en
Application filed by Smithkline Beecham Plc, Smithkline Beecham Lab filed Critical Smithkline Beecham Plc
Publication of NO20010293D0 publication Critical patent/NO20010293D0/no
Publication of NO20010293L publication Critical patent/NO20010293L/no

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/4261,3-Thiazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/427Thiazoles not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/02Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Organic Chemistry (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
NO20010293A 1998-07-21 2001-01-18 Anvendelse av glukoseopptaks-enhancer for redusering av post- ischemisk skade av hjertet NO20010293L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9815872.8A GB9815872D0 (en) 1998-07-21 1998-07-21 Novel method
GBGB9815871.0A GB9815871D0 (en) 1998-07-21 1998-07-21 Novel compound
PCT/GB1999/002358 WO2000004889A1 (fr) 1998-07-21 1999-07-21 Utilisation d'un activateur d'assimilation du glucose pour la reduction des lesions cardiaques d'origine ischemique

Publications (2)

Publication Number Publication Date
NO20010293D0 NO20010293D0 (no) 2001-01-18
NO20010293L true NO20010293L (no) 2001-03-07

Family

ID=26314086

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20010293A NO20010293L (no) 1998-07-21 2001-01-18 Anvendelse av glukoseopptaks-enhancer for redusering av post- ischemisk skade av hjertet

Country Status (35)

Country Link
EP (2) EP1098638B1 (fr)
JP (1) JP2002521325A (fr)
KR (1) KR20010079550A (fr)
CN (1) CN1167416C (fr)
AP (1) AP1416A (fr)
AR (1) AR020614A1 (fr)
AT (1) ATE318588T1 (fr)
AU (1) AU5053599A (fr)
BG (1) BG105251A (fr)
BR (1) BR9912144A (fr)
CA (1) CA2338216A1 (fr)
CO (1) CO5060465A1 (fr)
CY (1) CY1106078T1 (fr)
CZ (1) CZ2001250A3 (fr)
DE (1) DE69930125T2 (fr)
DK (1) DK1098638T3 (fr)
DZ (1) DZ2854A1 (fr)
EA (1) EA004772B1 (fr)
ES (1) ES2259839T3 (fr)
GC (1) GC0000173A (fr)
HU (1) HUP0103870A3 (fr)
ID (1) ID27850A (fr)
IL (1) IL140741A0 (fr)
MA (1) MA26662A1 (fr)
NO (1) NO20010293L (fr)
NZ (1) NZ509175A (fr)
OA (1) OA11583A (fr)
PE (1) PE20000881A1 (fr)
PL (1) PL345663A1 (fr)
PT (1) PT1098638E (fr)
SI (1) SI1098638T1 (fr)
SK (1) SK1022001A3 (fr)
TR (1) TR200100208T2 (fr)
TW (2) TWI239836B (fr)
WO (1) WO2000004889A1 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6417212B1 (en) 1999-08-27 2002-07-09 Eli Lilly & Company Modulators of peroxisome proliferator activated receptors
DZ3389A1 (fr) * 2000-06-16 2001-12-20 Smithkline Beecham Plc Traitement et prevention des etats associes de resistance cardiaque a l'insuline
AU2002319677B8 (en) 2001-07-23 2009-04-30 Atwater Management Llc Cytoprotective compounds, pharmaceutical and cosmetic formulations, and methods

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE186724T1 (de) * 1987-09-04 1999-12-15 Beecham Group Plc Substituierte thiazolidindionderivate
JPH05202042A (ja) * 1992-01-24 1993-08-10 Sankyo Co Ltd 糖尿病性合併症治療剤
GB9218830D0 (en) * 1992-09-05 1992-10-21 Smithkline Beecham Plc Novel compounds
GB9611947D0 (en) * 1996-06-07 1996-08-07 Glaxo Group Ltd Medicaments
US6277819B1 (en) * 1996-08-30 2001-08-21 Eli Lilly And Company Use of GLP-1 or analogs in treatment of myocardial infarction
IL128771A0 (en) * 1996-09-12 2000-01-31 Sankyo Co An agent for enhancing the activity of glutathione reductase containing troglitazone and use thereof
WO1999025346A1 (fr) * 1997-11-19 1999-05-27 Takeda Chemical Industries, Ltd. Nouvel inhibiteur d'apoptose
AU2781899A (en) * 1998-02-24 1999-09-15 Trustees Of The University Of Pennsylvania, The Use of a cardiac purinoceptor to effect cellular glucose uptake
AU4005299A (en) * 1998-05-19 1999-12-06 Regents Of The University Of California, The Thiazolidine and oxazolidine derivatives for the treatment of acute myocardial infarction and inhibition of cardiomyocyte apoptosis
US5968960A (en) * 1999-01-14 1999-10-19 The Regents Of The University Of California Use of thiazolidinediones to ameliorate the adverse consequences of myocardial ischemia on myocardial function and metabolism

Also Published As

Publication number Publication date
EP1523980A3 (fr) 2009-03-18
IL140741A0 (en) 2002-02-10
EP1098638B1 (fr) 2006-03-01
DK1098638T3 (da) 2006-06-19
SI1098638T1 (sl) 2006-06-30
PT1098638E (pt) 2006-07-31
CN1167416C (zh) 2004-09-22
TW200307532A (en) 2003-12-16
TWI239836B (en) 2005-09-21
PL345663A1 (en) 2002-01-02
ES2259839T3 (es) 2006-10-16
DE69930125D1 (de) 2006-04-27
CZ2001250A3 (cs) 2002-03-13
EA004772B1 (ru) 2004-08-26
AU5053599A (en) 2000-02-14
DZ2854A1 (fr) 2003-12-01
CN1310619A (zh) 2001-08-29
BR9912144A (pt) 2001-04-03
HUP0103870A3 (en) 2003-06-30
BG105251A (en) 2001-10-31
WO2000004889A1 (fr) 2000-02-03
EP1523980A2 (fr) 2005-04-20
EP1098638A1 (fr) 2001-05-16
PE20000881A1 (es) 2000-10-07
NO20010293D0 (no) 2001-01-18
GC0000173A (en) 2006-03-29
MA26662A1 (fr) 2004-12-20
ID27850A (id) 2001-04-26
ATE318588T1 (de) 2006-03-15
AR020614A1 (es) 2002-05-22
KR20010079550A (ko) 2001-08-22
CA2338216A1 (fr) 2000-02-03
SK1022001A3 (en) 2001-08-06
AP2001002033A0 (en) 2001-03-31
AP1416A (en) 2005-06-13
HUP0103870A2 (hu) 2002-05-29
EA200100164A1 (ru) 2001-08-27
JP2002521325A (ja) 2002-07-16
DE69930125T2 (de) 2006-10-05
NZ509175A (en) 2003-10-31
CO5060465A1 (es) 2001-07-30
OA11583A (en) 2004-07-01
TR200100208T2 (tr) 2001-05-21
CY1106078T1 (el) 2011-06-08

Similar Documents

Publication Publication Date Title
DK1051193T3 (da) Vandfrit topisk hudpræparat omfattende ketoconazol
ID28111A (id) Metoda untuk meningkatkan kesehatan kulit
NO20013770D0 (no) Metoder og blandinger for å öke antall hvite blodceller
ID28947A (id) Metode untuk meringankan inkontinensia uriner wanita
PT1198454E (pt) Derivados de mutilina e sua utilizacao como antibacterianos
DE69827245D1 (de) Ohrteil zur unterdrückung von lärm
DE60039796D1 (de) Vollständige Hämoglobinkonzentrations-Messung
EE200200203A (et) Südame arütmia ravis kasutatavad uued oksabispidiinühendid
EE04240B1 (et) (S)-omeprasooli kaaliumisool
LV12666B (lv) Antipikornavirusu savienojumi to iegusana un lietosana
ATE232378T1 (de) Reinigungspflaster zur verbesserung des hautzustandes
GB2352403B (en) Improvements relating to lancets
DE60031079D1 (de) Oberwellenmessung von Blockartefakten in Videosignalen
NO981774L (no) Fremstilling av L(+) - laktat
NO20015505L (no) Fremstilling av komplekse karbohydrater
NO20010293D0 (no) Anvendelse av glukose-opptaks-enhancer for redusering av post- ischemi skade av hjertet
RU2001120358A (ru) Применение ингибиторов натрий-водород-антипортера для получения лекарственного средства для ингибирования обусловленных возрастом дисфункций органов, обусловленных возрастом заболеваний и для продления жизни
ITMI991895A0 (it) Depigmentanti cutanei
FR2799755B1 (fr) Preparation de chlorure d'alcoylsufonyle perfluore en alpha du soufre
PT1178984E (pt) Derivados de 1-trifluorometil-4-hidroxi-7-piperidinilamimometilcromano
NO20010292D0 (no) Anvendelse av glukose-opptaks-enhancer for redusering av apoptose
ID29104A (id) Komposisi pemutih kulit untuk pemberian oral
DE60009069D1 (de) Bispidin-derivate zur behandlung von herzarrhythmien
SE9902389D0 (sv) Arrangement for non-invasive measurement of cardiac output
HU9903309D0 (en) Instrument to pick-up of dogfaeces